Anti-DLL4 ADCC Enhanced Antibody (MEDI0639) is an ADCC enhanced antibody produced by our Afuco™ platform. MEDI0639 is an investigational monoclonal antibody that selectively binds to Delta-like ligand 4 (DLL4) and blocks its ability to bind to and activate signaling through the Notch receptors, potentially inhibiting tumor growth by multiple mechanisms. Of 20 safety-evaluable pts, the most common treatment-related adverse events (trAEs) were increased aspartate aminotransferase, increased brain natriuretic peptide (BNP), and fatigue. No treatment-related deaths occurred. MEDI0639 150 mg did not exceed the MTD. Enrollment at the 200 mg dose level is ongoing. The safety profile is consistent with the mechanism of action and appears to be manageable. Preliminary evidence of antitumor activity was observed.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-204 | Anti-Human DLL4 Recombinant Antibody (TAB-204) | ELISA, FC, IP, FuncS, IF, Neut, WB | IgG2 - kappa |
There are currently no Customer reviews or questions for AFC-205CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.